Reorders for GLP-2 (Tirzepatide) flow through Qualiphy for clinical re-evaluation; GLP-3 and others ship after clinician review.
Program · GLP-1
Compounded Semaglutide
Mechanism: GLP-1 receptor agonist. Slows gastric emptying, reduces appetite, improves glycemic control.
Best for: first-time GLP users; steady, well-tolerated fat loss.
Expect: 5–15% body weight reduction over 6 months in most patients.
Program · GLP-2
Compounded Tirzepatide
Mechanism: Dual GLP-1 + GIP agonist. Greater fat loss and insulin sensitivity than GLP-1 alone in most patients.
Best for: patients ready for greater results; common upgrade from GLP-1.
Expect: 15–22% body weight reduction over 6–12 months.
Program · GLP-3
Compounded Retatrutide
Mechanism: Triple GLP-1 + GIP + glucagon agonist. The aggressive end of the metabolic ladder.
Best for: advanced patients; typically a step up from GLP-2 once tolerance is established.
Expect: larger absolute fat loss; tighter clinical monitoring required.
Adjunct
AOD-9604
Mechanism: Modified C-terminal fragment of human GH; lipolytic without affecting blood glucose.
Best for: stubborn-fat targeting, often used with a GLP program.
Adjunct
MOTS-C
Mechanism: Mitochondrial-derived peptide; AMPK pathway activation, glucose homeostasis, exercise capacity.
Best for: metabolic support and exercise tolerance in patients over 40.